James Frates Joins Amylyx Pharmaceuticals as Chief Economical Officer
The MarketWatch News Section was not included in the generation of this content.
Amylyx Pharmaceuticals, Inc., a pharmaceutical firm targeted on establishing new therapies for amyotrophic lateral sclerosis (ALS), Alzheimer’s Ailment and other neurodegenerative health conditions, today announced the appointment of James Frates as Main Economical Officer (CFO), effective Jan. 25, 2021. Mr. Frates joins Amylyx adhering to his tenure as CFO at Alkermes, given that 1998.
This press release features multimedia. View the whole release in this article: https://www.businesswire.com/information/property/20210114005141/en/
“We are so enthusiastic for Jim to join us at this significant juncture for Amylyx,” mentioned Joshua Cohen, Co-CEO, Chairman and Co-Founder of Amylyx. “Jim’s depth and breadth of knowledge as a biopharmaceutical government coupled with his fiscal acumen and private mission for bringing promising remedies to clients with ALS make him a fantastic addition to our leadership staff.”
“Jim provides the one of a kind blend of encounter with growing biopharma companies centered on the central anxious program, equally as a CFO and a board member, and enthusiasm for the persons we provide,” reported Justin Klee, Co-CEO and Co-Founder of Amylyx. “Jim evidently embodies our values and we are thrilled to have him sign up for our mission.”
Frates is an experienced leader who served as Alkermes CFO through its growth from a scientific phase organization to an worldwide professional and growth business with various products, around $1 billion in profits and in excess of 2000 personnel. Frates helped take care of the organization by way of many acquisitions and financings in the financial debt, equity and private markets. Prior to Alkermes, Frates worked as an financial investment banker at Robertson, Stephens & Corporation and Morgan Stanley. Frates at present serves on the Board of Sage Therapeutics, Inc., The Roxbury Latin School and St. Francis House in Boston. He is a graduate of Harvard College and acquired an MBA from the Harvard Graduate School of Enterprise Administration.
“Since my cousin Pete Frates was diagnosed with ALS in 2012, and by his incredible get the job done with the Ice Bucket Obstacle, I have felt a calling to become more associated in the struggle to locate a lot more successful therapies. I am eager to join Amylyx simply because it has built so substantially progress against neurodegenerative illnesses,” stated Frates. “I imagine my expertise can enable the company scale and provide on its guarantee of generating a medicine that can assist delay neurodegeneration in individuals. The option to assist battle ALS suggests a fantastic deal to me and my household.”
About Amylyx Prescription drugs
Amylyx Prescription drugs, Inc. is a pharmaceutical business working on producing a novel therapeutic for amyotrophic lateral sclerosis (ALS), Alzheimer’s condition and other neurodegenerative health conditions. For more information, take a look at www.amylyx.com and observe us on LinkedIn and Twitter.
View source edition on businesswire.com: https://www.businesswire.com/information/dwelling/20210114005141/en/
Supply: Amylyx Prescribed drugs, Inc.
Merissa Muller
Finn Associates
(617) 778-6633
[email protected]
COMTEX_377664930/2456/2021-01-14T08:00:46
Is there a challenge with this push launch? Call the resource company Comtex at [email protected]. You can also make contact with MarketWatch Client Provider through our Client Centre.
Copyright Business enterprise Wire 2021
The MarketWatch Information Office was not associated in the generation of this content.
